Myomo's mission is to restore function and independence to individuals with upper limb paralysis through its innovative MyoPro powered orthosis. The company has achieved commercial-stage status, securing critical Medicare reimbursement and building a growing body of clinical evidence to support adoption. Its strategy centers on a B2B2C model, expanding insurance coverage, and directly engaging clinicians and therapists to identify eligible patients within a large, underserved neurological rehabilitation market.
Non-invasive myoelectric sensing and pattern recognition algorithms that detect a user's residual nerve signals to control a powered, lightweight robotic arm orthosis for restoring functional movement.
Funding History
3
Total raised:$27M
IPO$12MUndisclosed
Series B$10MUndisclosed
Series A$5MUndisclosed
Opportunities
A large, underserved chronic patient population with upper limb paralysis exists, driven by stroke, injury, and neurological disease.
The recent establishment of a dedicated Medicare reimbursement fee schedule removes a major adoption barrier and provides a predictable payment model for growth.
Risk Factors
Commercial success is heavily dependent on securing and maintaining insurance reimbursement from Medicare and private payers.
The company's small size and financial resources pose execution risks in scaling manufacturing, sales, and clinical support to capture the market opportunity.
Competitive Landscape
Competes against clinic-based rehabilitation robots (e.g., ReWalk Restore, EksoUE) and indirect alternatives like passive braces. Myomo's key differentiation is its focus on non-invasive, user-controlled, daily home and community use for functional restoration, rather than supervised clinical therapy.
